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Abstract
Background: Osteoarthritis (OA) is a debilitating chronic multijoint disease of global proportions. OA presence and severity
is usually documented by x-ray imaging but whole body imaging is impractical due to radiation exposure, time and cost.
Systemic (serum or urine) biomarkers offer a potential alternative method of quantifying total body burden of disease but
no OA-related biomarker has ever been stringently qualified to determine the feasibility of this approach. The goal of this
study was to evaluate the ability of three OA-related biomarkers to predict various forms or subspecies of OA and total body
burden of disease.
Methodology/Principal Findings: Female participants (461) with clinical hand OA underwent radiography of hands, hips,
knees and lumbar spine; x-rays were comprehensively scored for OA features of osteophyte and joint space narrowing.
Three OA-related biomarkers, serum hyaluronan (sHA), cartilage oligomeric matrix protein (sCOMP), and urinary C-
telopeptide of type II collagen (uCTX2), were measured by ELISA. sHA, sCOMP and uCTX2 correlated positively with total
osteophyte burden in models accounting for demographics (age, weight, height): R
2=0.60, R
2=0.47, R
2=0.51 (all p,10
26);
sCOMP correlated negatively with total joint space narrowing burden: R
2=0.69 (p,10
26). Biomarkers and demographics
predicted 35–38% of variance in total burden of OA (total joint space narrowing or osteophyte). Joint size did not determine
the contribution to the systemic biomarker concentration. Biomarker correlation with disease in the lumbar spine
resembled that in the rest of the skeleton.
Conclusions/Significance: We have suspected that the correlation of systemic biomarkers with disease has been hampered
by the inability to fully phenotype the burden of OA in a patient. These results confirm the hypothesis, revealed upon
adequate patient phenotyping, that systemic joint tissue concentrations of several biomarkers can be quantitative
indicators of specific subspecies of OA and of total body burden of disease.
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Introduction
Osteoarthritis (OA) is a debilitating chronic multijoint disease
with major global impact [1]. OA presence and severity is usually
documented by x-ray imaging but whole body imaging is
impractical due to radiation exposure, time and cost. Systemic
(serum or urine) biomarkers offer a potential alternative method of
quantifying total body burden of disease but no OA-related
biomarker has ever been stringently validated to determine the
feasibility of this approach. Systemic biomarkers in OA are usually
only assessed relative to a particular joint site under study. The
advent of disease status indicators in the serum or urine would
provide badly needed objective means of evaluating and
monitoring the disease, could provide quantitative traits for
genetic studies, and could contribute to identifying individuals at
greatest risk of progression, and therefore, in greatest need of
prevention strategies.
The inference of the relevant relationships between serum or
urine biomarker concentrations and disease of specific joints is
complicated by the fact that many or most OA patients have
disease in multiple joints. Moreover, OA is a complex disease
increasingly understood to be a mixture of distinct clinical and
genetic entities [2,3,4,5]. OA of the knee may or may not share the
same etiology as OA of the spine or hands. Biomarkers may be
useful as indicators of specific subspecies of OA, or of OA in
specific joints. The distinct features of radiographic OA of joint
space loss and osteophyte represent different disease processes that
may also differ in their associations with biomarkers. These
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correlation in order to test the independent association of
biomarkers with particular features of OA. Any study aimed at
elucidating these relationships will need to collect extensive
radiological data to survey all joints potentially involved in OA.
Only a small fraction of the patients analyzed will have OA
isolated to one set of joints [6]. To focus on this small fraction of
the total data would be wasteful and unsatisfying. Instead, we have
chosen to analyze the full dataset, relying on statistical analysis,
model selection, and model averaging to disentangle the web of
correlations among radiological disease, OA risk factors, and
biomarkers.
Qualification is the evidentiary process of linking a biomarker
withbiological processesandclinical endpoints [7]. Inthiswork,we
focus on the process of biomarker qualification for structural
endpoints of OA, such as osteophyte formation and radiographic
joint spacenarrowing,as opposed to symptomatic endpoints suchas
joint pain. We chose to analyze three biomarkers in this study based
on the strength of previous evidence showing associations with OA:
serum hyaluronan (sHA), serum cartilage oligomeric matrix protein
(sCOMP), and urinary C-terminal propeptide epitope of collagen II
(uCTX2). Each of these biomarkers has data to support its
classification [8] in at least two categories of the BIPED [9]
biomarker classification scheme (Burden of disease, Investigational,
Prognostic, Efficacy of intervention, and Diagnostic biomarkers).
The categories to which each of these biomarkers corresponds for
structural features of OA are as follows: HA–categories D, B, P, E
[10,11,12,13,14,15,16]; COMP–categories D, B, P [16,17,18];
CTX2–categories D, B, P E [10,15,19,20,21,22,23].
In this work we describe which radiological features are associated
with each systemic biomarker and the extent to which these
biomarkers reflect burden of disease of the various forms and features
o fO A .H e r ew eh a v eq u a l i f i e dt h e s et h r e eb i o m a r k e r sa ss t r o n g
quantitative traits of various features of OA. Uncoupling these
features or processes of OA provided insights into the origin of these
biomarkers. We observed that the canonical radiographic features of
OA, namely osteophyte and joint space narrowing, correlated with
one another, often in a complex manner with regard to their effects on
a biomarker. We further observed that small joints did not necessarily
contribute in a small way to serum biomarker concentrations.
Moreover, with respect to the impact on biomarkers, the lumbar spine
radiographic features behaved similarly to radiographic features in
other joints, arguing for a similar disease process ongoing in the
lumbar spine as in the rest of the skeleton. Finally, systemic
biomarkers were more powerful predictors of multijoint disease than
of disease in any single joint when added to a statistical model
containing risk factor data (age, height, and weight). A notable
exception was the knee in which biomarkers doubled the power of
these factors alone for predicting radiographic features of OA.
Results
Participant characteristics
A total of 461 female participants were studied. Their mean
(SD) age was 67 (10) years old. Their mean (SD) weight, height
and body mass index were 74 (17) kg, 161 (7) cm, and 28 (6)_(kg/
m
2), respectively. Just over two-thirds of the participants were
evaluated through the Duke site (n=322) and the remainder at the
UNC site (n=139).
Correlations and bilateral symmetry among radiographic
features of OA in the various joint systems
There were seven distinct joint systems considered: distal (DIP)
and proximal (PIP) interphalangeal finger joints, metacarpopha-
langeal (MCP or knuckle) hand joints, carpometacarpal (CMC or
base of thumb) joints, knees, hips and lumbar spine. Figure S1A-B
shows the age-related increased prevalence of affected joint
systems based on any osteophyte or any joint space narrowing
scores; Figure S1C shows the numbers of subjects by decade of age
with with the OA affected joint system based on the Kellgren
Lawrence grade .1 grade (Fig. S1C). age-related increased
prevalence of affected joint systems based on the traditional
Kellgren Lawrence (KL) grading system [24] (quantified in Table
S1).
Figure 1 shows the correlation matrix among joints affected by
osteophyte (OST), and by joint space narrowing (JSN), a surrogate
for cartilage loss. The tapestries are complex, reflecting the
inherent complexity of OA, but the departures from randomness
apparent in their patchiness and symmetries provide important
insights into the relationships among the manifestations of disease
in the various joints. Two interesting features are discernible in this
figure. First, joint faces (medial, lateral, superior and inferior joint
margins) within the same joint tended all to be affected by OST, as
indicated by the appearance of square patches in the resulting
tapestry of this matrix (Figure 1A), particularly in the knees, hands
and lumbar spine. Such correlation within joints was less evident
for JSN (Figure 1B) but still apparent in the hands, and to a lesser
extent, the lumbar spine. Second, there was a high degree of
bilateral symmetry in the distribution of OA in these study
participants as indicated by the mirror-image symmetry of both
panels of Figure 1 across the diagonal. In the JSN tapestry
(Figure 1B), this bilateral symmetry extended even to the
preferential correlation of the same specific joint faces in
contralateral joints, as was especially apparent, for example, in
the knees and hips (shown by the strong backward diagonal line).
In addition, there was greater collateral involvement of neighbor-
ing joints on the right hand, based on JSN, than the left hand (top
right versus bottom left corner of Figure 1B). This further
highlights the striking multi-joint OA involvement of individuals
recruited on the basis of hand OA alone.
For each participant, we summed the total number of joint faces
with OST .0 and the total number of joints with JSN .0,
designating these sums nOST and nJSN, respectively. We also
summed the total number of joints with OA based on KL scoring
(KL.1), designating this sum nKL. Among participants, nOST and
nJSN had a correlation coefficient of r=0.66, which was very highly
significant (p,10
26).
Associations of biomarkers and radiological features of
OA
The OA-related biomarkers, serum hyaluronan (sHA) and
urinary C-telopeptide fragment of type II collagen (uCTX2), were
strongly positively correlated with the number of affected joint
systems based on KL scoring, with their concentrations having
significantly positive coefficients in a linear model with nKL as a
predictor (Figure S2). Quite surprisingly, serum cartilage oligo-
meric matrix protein (sCOMP) showed a statistically significant
(p=0.024) concentration decrease as nKL increased. Note that
these models were fit with the following risk factors: [12,17,25]
age, log height, log weight for sHA; age for sCOMP; and for
uCTX2 no other covariate was used. These covariates were tested
based on their significance in previous work [12,17,25,26,27],and
those used for these analyses were based on their significant
association with OA in models that included the biomarkers.
The KL scoring system is a composite variable, consisting of
some OST and some JSN criteria. To assess these features
uncoupled, we evaluated the association of the biomarkers to OST
and JSN in models fit with the risk factors noted above and with
Biomarkers and Osteoarthritis
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regard to which joint they belonged to and we accounted for
correlations among features. Accounting for correlation with JSN,
all three biomarkers showed a positive dose-dependent relation-
ship with total OST burden (p,10
26). In contrast, although sHA
and uCTX2 showed a strong positive dose-dependent relationship
with total JSN burden before adjustment for OST (Figure S3),
there was no significant association of sHA or uCTX2 with JSN
after accounting for correlation with OST (Figure 2). Surprisingly
perhaps, and in contrast to sHA and uCTX2, sCOMP showed a
negative dose-dependence with total JSN-affected faces, even after
accounting for OST (Figure 2). Some of the most striking
associations between individual biomarkers and specific radio-
graphic features are shown in Figure S4: namely sHA and knee
OST and CMC JSN; sCOMP and DIP JSN (inverse correlation);
and uCTX2 and hip OST.
We next computed the regression coefficients for each
biomarker (dependent variable) for each joint site and radio-
graphic feature (independent variables) in a mixed-effects model
with all 14 distinct radiographic features (OST and JSN for each of
7 joint systems) included as predictors. This ‘‘saturated’’ model was
not optimally predictive (we developed an optimized model
below), but it did allow us to effectively decouple the correlations
among the independent variables that would otherwise confound
Figure 1. Correlation matrix of radiographic features of osteoarthritis. The correlation for left and right joints are shown for A) osteophyte
score in each pair of joint faces, B) joint space narrowing score for each pair of faces. Each cell indicates the correlation between two joint faces as
indicated in the color legend. The correlation matrix is symmetric by definition across the main diagonal. Left and right sides of the body are depicted
from bottom to top on the y-axis and from left to right on the x-axis.
doi:10.1371/journal.pone.0009739.g001
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9739Figure 2. Biomarkers and total burden of OA based on radiographic features (adjusted). The data are restricted to female subjects with
complete radiographic and biomarker data. The data were fit to a mixed-effects model, with family as the grouping variable for the random effect.
The fixed effects are the numbers of joint faces affected by osteophytes and joint-space narrowing, respectively. Point estimates are plotted for mean
serum log sHA (top), log sCOMP (middle), and log uCTX2 (bottom) by number of joint faces affected by any osteophyte (grade .0, left panels), and
number of joint faces OA affected by any joint space narrowing (grade .0, right panels). Joint faces are counted without regard to which joint they
belong. JSN point estimates account for OST and OST point estimates account for JSN. In addition, sHA was adjusted for age, log height, log weight;
sCOMP was adjusted for age; and CTX2 did not require adjustment. The R
2 values indicated give the proportion of the inter-radiographic class
variation explained by the regression. The respective generalized R
2 values for the variance explained by the radiographic features are 4.4%, 6.2%,
and 10.2%. All p-values for the weighted regressions are less than 10
26, except for the pairing of sHA and JSN (p=0.18), and uCTX2 and JSN (p=0.51).
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biomarkers, and to evaluate the contributions of each in its
natural context. In Figure 3, a visual comparison is shown of these
coefficients considered jointly, through simultaneous fits to all
radiographic features; Figure S5 shows the same coefficients
estimated by fitting to single radiographic features individually, i.e.
not accounting for correlations among features. In both cases, the
horizontal reference lines are located at the common coefficient
value obtained by considering all joints equivalent, ie, constraining
all joints to have identical coefficients. Coefficients significantly
above these lines identify features of a particular joint that
contribute disproportionately (higher than expected assuming
equivalence among joint systems) to the respective biomarker
concentrations–while coefficients below the reference lines identify
features of a particular joint that provide less than the average
contribution to the respective biomarker concentration. Notewor-
thy findings illustrated in Figure 3 include the fact that CMC JSN
contributed disproportionately (positively) to all three biomarker
concentrations, while CMC OST had the opposite tendency
(disproportionate negative contribution). Knee OST and knee JSN
contributed greater than average levels to both sHA and uCTX2.
These plots again demonstrate the positive association of sCOMP
with OST, but a negative association, with the exception of JSN of
the CMC, of sCOMP with JSN.
Due to the interrelationship of JSN and OST, (illustrated below
for the CMC joint and an issue for most other joints as well),
misleading conclusions can be drawn by examining given
radiographic features in isolation from the rest. Figure S5 (lower
panel) shows the results of such an unadjusted analysis, where
OST or JSN in each joint was used as the sole predictor for
uCTX2. There are some notable differences between these results
and those shown in the uCTX2 panel of Figure 3 (adjusted). In
both the unadjusted and adjusted analyses, uCTX2 is associated
with CMC JSN. In contrast, uCTX2 was associated with CMC
OST in the unadjusted analyses but when OST and JSN are
accounted for in all joints, the association of uCTX2 and OST not
only declined, it became nominally negative, with borderline
statistical significance. Figure S6 illustrates the interaction of OST
and JSN as contributors to uCTX2 for the CMC joint. It shows
that when CMC joint faces affected by OST are measured alone
they indicate the likelihood of joint faces affected by JSN, which in
turn is predictive of increased levels of uCTX2. If both CMC JSN
and OST are measured, greater OST involvement predicts a
lower uCTX2 concentration.
Optimal prediction of biomarker concentration
Because radiographic features have the potential to confound
each other, we set out to determine the best combination of
features for the prediction of biomarker concentrations. We
considered all linear mixed-effects models with family, age, height,
and weight as well as JSN and OST of each of the seven joint
systems as possible linear predictors. For some analyses, we
combined PIP and DIP finger joints into a single class,
interphalangeal joints (IP). Since each of these terms can be either
included or excluded in any given model, there are 2
17=131,072
models to evaluate, which we did exhaustively. We used the
Akaike Information Criterion (AIC) [28,29] to evaluate each
model. The resulting optimal models are shown in Table 1.
Notably, uCTX2, distinct from the other two biomarkers, had no
significant relationship to age, height or weight after accounting
for the radiographic features of OA. IP JSN was negatively
predictive of sCOMP concentrations. In addition, we computed
the Akaike importance weights to examine the relative importance
of each joint system apart from their role in the single optimal
model (Figure 4). The Akaike weight for a given model is
proportional to exp(-AIC/2). The weights are normalized to sum
to one over all models in the class under consideration. The Akaike
importance weight for a predictor is the sum of Akaike weights
over all models in which that predictor is included. The Akaike
importance weights (0–1) are intended to provide a measure of the
importance of a predictor with respect to a whole class of models,
rather than to any individual model, and are thus robust against
model mis-specification [29]. Shown in Table 1 (taking into
account all joints): sHA reports on MCP JSN, CMC JSN, hip
OST and knee OST; sCOMP reports on IP JSN (inverse
correlation), MCP OST, MCP JSN (inverse correlation), lumbar
spine OST, and knee OST; and uCTX2 reports on CMC OST
(inverse correlation), CMC JSN, lumbar spine OST, hip OST and
knee OST.
Use of serum biomarkers to predict OA
Ultimately, we are interested in the information about disease
state that measurement of these serum biomarkers can convey.
Moreover, because of the wide distribution of predictive covariates,
it is plausible that the use of all three systemic biomarkers could
suffice to identify which joint-system is affected. To take steps in this
direction we sought to determine which covariates, including risk
factors (age, height, and weight) and biomarkers, are most useful for
predicting the OA burden in each of the joint systems studied. For
this purpose we used exhaustive testing of all 2
6=64 linear
regression models with interactions among predictors excluded for
each of the 266 outcomes of interest. The outcome variables used
were the percent maximum osteophyte burden and percent
maximum joint-space narrowing burden, defined as the sum of
the radiographic osteophyte or joint-space narrowing scores,
respectively, over all joints within each of the six joint systems, or
over all joints in total, divided by the maximum of the relevant sum
(maximum sum scores for radiographic features provided in Table
S2), and expressed as a percentage. Model selection, as above, was
based onthe AIC.Todeterminetheproportionofthetotalvariance
attributable to the biomarker component of the model, we
recomputed the regression with the biomarkers removed. The
results of these analyses for total body burden, including Akaike
importance weights, are presented in Table 2; complete results for
all joint systems are presented in Supplementary Table S3. In all
cases, namely individual joint systems and total body burden of
disease, the addition of biomarkers to traditional covariates
increased the proportion of variance in OA explained. A total of
35–38% of the variance in total body burden of OA (total JSN or
total OST) was accounted for by the full model with all three
biomarkers, a much smaller proportion of the variance was
accounted for in the individual joint systems (Table S3). Total
body burden of OST could be optimally predicted with sHA and
uCTX2alone,whiletotalbodyburdenofJSNwas bestpredictedby
the use of all three biomarkers.
Discussion
We have suspected for some time that the correlation of
systemic biomarkers with disease has been hampered by the
The mean (standard deviation) and range of biomarker concentrations prior to logarithmic transformation were: sHA mean 50.7(56.5) ng/ml, range:
1.1–499 ng/ml; sCOMP mean 1130(620) ng/ml, range: 203–4903 ng/ml; uCTX2 mean 372(806) ng/mmol, range: 19.6–12,171 ng/mmol.
doi:10.1371/journal.pone.0009739.g002
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9739Figure 3. Plot of linear coefficients of biomarker concentrations and radiographic features of OA for 7 joint systems (adjusted). The
linear coefficient was derived for the association of each biomarker with OST and JSN for each joint site. The mean linear coefficient from all joint sites
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sense, giving systemic biomarkers a ‘bad name’. The results
presented here illustrate the strong correlation of total body
burden of disease and several biomarkers, revealed upon adequate
patient phenotyping. These results clearly show that all three
biomarkers, sHA, sCOMP and uCTX2 are quantitative traits of
the radiographic feature of OST while sCOMP is a negative
indicator of joint space narrowing affected joint faces in the body.
This paper may serve some in the relevant medical communities as
an introduction to some novel methods for assessing biomarkers in
combination, joint systems in combination, and OA features in
combination. For instance, evaluated in combination using
multimodel inference with linear mixed-effects regression, it
becomes evident that sCOMP adds little information for
predicting total OST burden when sHA and uCTX2 are available,
although sCOMP is a marker of osteophytes.
There have been several previous studies that used OA-related
biomarkers in combination to quantify and characterize the OA
process [16,19,26,30,31,32]. Four notable examples [16,26,31,32]
used principal components analysis (PCA). Meulenbelt et. al.
identified three components that reflected radiographic OA at
different joint sites. The components werecomprised of 1) structural
markers of cartilage (uCTX2, uTINE, uGlc-Gal-PYD) and bone
turnover (uCTX-1 and total sOsteocalcin) associated with hip
radiographic OA; 2) a marker of inflammation (serum hsCRP)
associated with knee OA, high Western Ontario and McMaster
Universities (WOMAC) scores and BMI; and 3) markers of cartilage
turnover (sPIIANP, sCOMP) associated with radiographic OA of
the hands and lumbar spine as well as age. PCA by Davis et. al. has
also identified several factors based on biomarkers that correlated
with OA features: 1) a factor representing osteophytes that
overlapped, as expected, with a factor that correlated with Kellgren
Lawrence score; 2) a separate factor that correlated with
subchondral bone mineral density; and 3) a factor that correlated
with joint space width that overlapped with biomarkers associated
with both osteophytes and bone mineral density [16]. In work by
Garnero et al [31], 10 markers segregated into 5 factors: Factor 1
comprised markers of bone (S-PINP, U-CTX-I) and cartilage (U-
CTX2) turnover; factor 2 comprised of SCOMP, S-HA, and S-
PIIINP; factor 3 comprised of markers of systemic inflammation S-
CRP and S-YKL-40; and factors 4 and 5 comprised of MMP-1 and
MMP-3 respectively. Prior work by Otterness et al [32] showed that
14 biomarkers segregated into 5 rational groups based on
inflammation, bone turnover, cartilage anabolism, cartilage catab-
olism and transforming growth factor beta.
These studies support our finding that different biomarkers
report on different aspects of joint pathology. Specifically, different
biomarkers may reflect different molecular pathobiologic mecha-
is represented by the red line (for OST) and the blue line (for JSN) depicting the strength of the association. The coefficients are shown for serum log
sHA (top), log sCOMP (middle), and log uCTX2 (bottom) by number of joint faces affected by any osteophyte (grade .0), and number of joint faces
affected based on any joint space narrowing (grade .0). All features were included in each model to assess the contribution of each feature in the
presence of the others, i.e. we accounted for correlations among features. Error bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0009739.g003
Table 1. Covariates and their coefficients comprising the minimum-AIC models for predicting sHA, sCOMP and uCTX2.
OA Feature sHA sCOMP uCTX2
age 0.018 (0.005) 0.009 (0.003)
weight 0.49 (0.18)
height 22.75 (0.90)
IP OST
JSN 20.023 (0.005)
MCP OST 0.023 (0.012)
JSN 0.036 (0.022) 20.026 (0.014)
CMC OST 20.163 (0.084)
JSN 0.165 (0.046) 0.270 (0.089)
Lumbar Spine OST 0.019 (0.008) 0.029 (0.015)
JSN
Hip OST 0.042 (0.030) 0.080 (0.034)
JSN
Knee OST 0.050 (0.011) 0.013 (0.006) 0.083 (0.012)
JSN
R
2 without radiographic data 15.3% 0.1% NA
R
2 with radiographic data 24.3% 8.8% 16.5%
The numbers are parameter estimates with their standard errors in parentheses.
AIC = Akaike’s Information Criterion.
Percent biomarker variance explained (generalized R
2) with and without radiographic data (i.e. IP MCP, CMC, spine, hip and knee data).
IP = interphalangeal (distal and proximal) finger joints.
MCP = metacarpophalangeal (knuckle) hand joints.
CMC = first carpometacarpal (base of thumb) joint.
sHA = serum hyaluronan.
sCOMP = serum cartilage oligomeric matrix protein.
doi:10.1371/journal.pone.0009739.t001
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concentrations. The interpretation of biomarker levels may be
further complicated by the complex biology represented by a
biomarker. For instance, decreased levels may reflect reduced
matrix degradation, decreased synthesis, or impaired release from
the tissue or origin [33]. Osteophyte formation can be considered
an anabolic phenomenon and all three biomarkers reported
independently on this feature of joint pathology. In contrast, joint
space narrowing can be considered a phenomenon of catabolism
in excess of anabolism, or a net failure of repair. The negative
correlation of COMP and joint space narrowing could represent
the failed repair phenomenon (waning of an anabolic epitope) with
increased disease severity, or depletion of a catabolic epitope with
increased disease severity. In this cohort, neither HA nor CTX2
reported independently on JSN. These findings only came to light
with comprehensive phenotyping that demonstrated the utility of
total body measures of OA when qualifying a systemic OA-related
biomarker for a specific purpose. Moreover, these results also
highlight the importance of accounting for both OST and JSN.
Failure to account for both is problematic and may lead to
spurious conclusions as demonstrated here through comparing
and contrasting the results obtained from adjusted versus
unadjusted analyses (Figure 2 versus Figure S3, and Figure 3
versus Figure S5).
Figure 4. Akaike importance weights for each radiographic feature in linear models for the biomarker concentrations. All first-order
linear models were fit, and the Akaike weight computed for each one. The bar height is the Akaike importance weight, the sum of the Akaike weights
over all models: the greater the height, the more predictive of biomarker concentration.
doi:10.1371/journal.pone.0009739.g004
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sCOMP increased with age; uCTX2 was also independent of
height and weight, as was sCOMP while sHA increased with
weight and decreased with height. The biomarkers increased the
variance explained over simple demographic factors for predicting
total body burden of disease. The different proportions of variance
explained by biomarkers for the different joint systems may be
related to genetic variation or to measurement variation, i.e.
adequacy of phenotyping. In this regard, it is interesting that
biomarkers added most to the prediction of knee OA, for which a
standardized radiographic phenotyping procedure was used. This
specialized x-ray may more accurately represent the disease. Thus,
the biomarkers may not be so marginal but rather, true
correlations of systemic biomarkers with disease burden may be
higher, and only demonstrable with better gold standards for
measuring the disease.
The coefficients of a linear model estimate the average
contribution per affected joint to the serum concentration of a
biomarker. OST and JSN had very similar coefficients for sHA
and uCTX2, however, there were cases where the difference
among OST and JSN were significant and may have real
consequences for the use of these biomarkers. One example of
the potential complex interrelationship of OST and JSN was
demonstrated by the increase of uCTX2 with increasing number
of CMC joint faces affected by JSN. When the number of joint
faces affected by JSN was held constant, however, uCTX2
declined with increasing number of CMC joint faces affected by
OST. Another point, convincingly demonstrated herein by the
large contribution of CMC-OST to both sHA and uCTX2
concentrations, is that joint size does not necessarily determine the
contribution of a joint to the systemic biomarker concentration.
One could truly say, based on these data that the CMC ‘‘sticks out
like a sore thumb’’. We do not know why the CMC joint, despite
its small size, disproportionally impacted the concentration of all
three systemic biomarkers. It is possible that the stage of disease
accounted for this phenomenon. For instance, relative to other
joints, increasing JSN in the CMC represented increasingly active
matrix turnover while increasing CMC osteophyte severity, an
anabolic phenomenon, represented waning activity with respect to
biomarker production. Another possible explanation relates to
relative turnover and clearance of the biomarkers from the CMC
joint. Strong evidence exists for differences in joint tissue turnover
for different joint systems, best exemplified by differences between
knees and ankles [34].
Radiographic features of OST and JSN are interrelated and this
correlation can prove to be a potential confounder in attempts to
characterize the independent contributors to the systemic level of a
biomarker. There are just two examples of OST and JSN features
from a single joint system contributing independently to the
concentration of a systemic biomarker: MCP on sCOMP, and
CMC on uCTX2 (Table 1). In both cases, JSN and OST features
had opposing effects on biomarker concentration. This study was
limited to women, so these results will need to be validated in other
cohorts, including men, selected by other means. Further, because
the study participants were selected on the basis of familial hand
OA, they may have had greater correlation of OA among joint
sites than individuals without so clearly a familial etiology of OA.
For this reason, the generalizability of these results would need to
be evaluated. Finally, these analyses were limited to the association
of a discrete set of biomarkers and structural changes. The field
would benefit from similar analyses of a broader range of
biomarkers, and qualification studies related to clinical and
symptomatic patient-reported outcomes to complement those
presented here related to structural endpoints.
Materials and Methods
Ethics statement
Written informed consent was obtained from all participants
and the study was approved by the institutional review boards of
both Duke University and the University of North Carolina at
Chapel Hill. The investigation was conducted in accordance with
the principles expressed in the Declaration of Helsinki.
Participants
The participants for these analyses were enrolled between 1999
and 2002 in the GOGO (Genetics of Generalized Osteoarthritis)
study and evaluated at two sites (Duke University and the
University of North Carolina at Chapel Hill) [6]. A qualifying
family consisted of at least 2 siblings with self-reported Western
European descent who fulfilled clinical GOGO hand OA criteria:
bony enlargement of $3 joints distributed bilaterally, including
bony enlargement of at least one DIP joint, and no more than 3
swollen MCP joints. Recruitment was independent of clinical
symptoms. Once the sibling pair was positively identified as being
clinically affected, the nuclear family was invited to participate,
together with potential affected or unaffected siblings beyond the
required two affecteds. The cohort consisted of 1060 individuals,
840 women and 220 men. Serum and urine biomarker analyses
were conducted on the 461 women from this cohort for whom full
radiographic data were available. For this study we focused on the
461 women because OA patterns may vary between sexes.
Phenotypic Characterization
Weight and height were measured. Participants underwent
radiographic evaluation of both hands, hips, knees and lumbar
spine as previously reported [6]. Radiographs were scored for
Kellgren Lawrence grade (0–4 scale) [24], and individual
radiographic features of OA, osteophyte (OST) and joint space
narrowing (JSN), on a 0–3 scale using a standard photographic
radiological atlas [35]. All joints, including the lumbar spine, were
scored for OST. JSN was scored for DIP, PIP and CMC finger
joints, MCP hand joints, knees and hips. The lumbar spine was
graded for disc space narrowing which, for purposes of these
Table 2. Predictors and their coefficients comprising the
minimum-AIC models for percentage of maximum
osteoarthritis burden.
Total burden Akaike importance
OST JSN OST JSN
age 0.33 (0.03) 0.52 (0.05) 1.00 1.00
weight 2.12 (1.35) - 0.82 0.42
height - - 0.41 0.28
sHA 1.39 (0.37) 1.84 (0.53) 1.00 0.99
sCOMP - 22.70 (0.82) 0.30 0.99
uCTX2 2.35 (0.31) 2.04 (0.45) 1.00 1.00
R
2 no biomarkers 26% 28%
R
2 with biomarkers 38% 35%
AIC = Akaike’s Information Criterion.
sHA = serum hyaluronan.
sCOMP = serum cartilage oligomeric matrix protein.
uCTX2 = urinary C-terminal telopeptide of type II collagen normalized to
urinary creatinine.
doi:10.1371/journal.pone.0009739.t002
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the case of lumbar spine) were graded for these features. The
scoring system and possible scores for each joint system are
summarized in Table S2 and the number of affected joint systems
by KL grade is provided in Table S1. Of the phenotypic data
collected, age, and measured weight and height were used in these
analyses.
Biomarker Analyses
Blood for sera, and an aliquot of unspun urine, were collected
and stored at 280uC for biomarker analyses. Serum samples were
analyzed in duplicate for sHA using a commercially available kit
(Corgenix, Westminster, CO), and sCOMP using an in-house
enzyme-linked immunosorbent assay (ELISA) as previously
described [36]. The minimum detectable concentrations of sHA
and sCOMP were 10 ng/ml and 120 ng/ml, and intra-and inter-
assay coefficients of variation (CVs) were ,5% and ,7% for sHA,
and 2.1% and 14.2% for sCOMP. Urinary CTX2 (Nordic
Bioscience Diagnostics CartiLapsH, Herlev, Denmark) was
measured per the manufacturer’s instructions by competitive
ELISA to detect the degradation product, C-terminal telopeptides
of type II collagen (uCTX2) in urine samples. The concentration
of creatinine was measured using a commercially available
colorimetric kit (METRA
TM QUIDEL Corp., San Diego, CA),
and uCTX2 values were corrected for urine creatinine concen-
tration (mmol/L). The minimum detectable concentration of
uCTX2 is reported as 0.20 ng/ml by the manufacturer. Intra-and
inter-assay CVs were 5.9% and 9.9%, respectively. There is strong
evidence for association with OA at specific joint sites for each of
these biomarkers [12,17,25,37,38,39] but association with total
body burden of disease has not been attempted previously.
Statistical Methods
All statistical analyses were performed using S-Plus 7.0 (Insightful
Corp). For each of the three proteins (sHA, sCOMP and uCTX2),
we fit linear mixed-effects models using family as the random factor.
These modelsallowed us to account forthepossibility that there was
an inheritable component of constitutive levels of expression for
these proteins given that most subjects had one or more relatives in
the database. Model estimation was done using Maximum
Likelihood (rather than Restricted Maximum Likelihood) to permit
comparisons among models using Akaike’s Information Criterion
(AIC). AIC provides a score that represents the balance between
model fit and the number of parameters (model complexity) [29].
Lower values for the AIC indicate more suitable models. Predictor
selection was performed using AIC and exhaustive enumeration of
all first-order linear models over both mixed-effects models and
fixed-effects models (the latter of which exclude family as a
predictive covariate). R
2 values reported for mixed-effects models
are computed using Nagelkerke’s generalized R
2 [40]. Model
averaging was performed by computing the Akaike weight for each
model as C exp {AIC=2 ðÞ where C is a normalizing constant, and
summing over all first-order linear models [29]. Adjustments for the
risk factors age, height, and weight were made individually for each
biomarker by finding the combination of these factors that give the
lowest AIC. This procedure provided the ‘‘base model’’ against
which all further comparisons were made.
The S-language scripts used to run these analyses are available
upon request.
Supporting Information
Table S1 Classification of participants (N=461) by radiographic
osteoarthritis status.
Found at: doi:10.1371/journal.pone.0009739.s001 (0.03 MB
DOC)
Table S2 Scoring system for radiographic features of osteoar-
thritis.
Found at: doi:10.1371/journal.pone.0009739.s002 (0.04 MB
DOC)
Table S3 Predictors and their coefficients comprising the
minimum-AIC models for percentage of maximum osteoarthritis
burden.
Found at: doi:10.1371/journal.pone.0009739.s003 (0.06 MB
DOC)
Figure S1 Age-related prevalence of OA based on radiographic
features. Prevalence (total number of cases in the age group,
divided by the number of individuals in the age group) of OA of
affected joint systems based on any osteophyte (Fig. S1A), or any
joint space narrowing (Fig. S1B) by decade of age. The error bars
show exact binomial 95% confidence intervals. The numbers of
subjects with OA of affected joint systems based on the Kellgren
Lawrence grade .1 grade (Fig. S1C) by decade of age. The joint
subtypes evaluated included the interphalangeal (IP) finger joints
(combination of distal and proximal interphalangeal joints),
metacarpophalangeal (MCP or knuckle) hand joints, carpometa-
carpal (CMC or base of thumb) joint, lumbar spine, hip, and knee
joints.
Found at: doi:10.1371/journal.pone.0009739.s004 (0.25 MB
PDF)
Figure S2 Biomarkers and number of affected joint systems
based on traditional Kellgren Lawrence (KL) scoring. Mean log
sHA (top), log sCOMP (middle), and log uCTX2 (bottom), by
number of affected joint systems with OA based on Kellgren
Lawrence (KL) grade .1. These models were fit with the
following risk factors: age, log height, log weight for sHA; age
for sCOMP; and for uCTX2 no other covariate was used. The
respective R2 values, giving the proportion of the among-KL
grade variation explained by the linear regression are shown.
Accompanying p-values are 3.661027, 0.024, and 3.661025.
Found at: doi:10.1371/journal.pone.0009739.s005 (0.66 MB TIF)
Figure S3 Biomarkers and total burden of OA based on
radiographic features (unadjusted). Point estimates are plotted
for mean serum log sHA (top), log sCOMP (middle), and log
uCTX2 (bottom) by number of joint faces affected by any
osteophyte (grade .0, left panels), and number of joint faces OA
affected by any joint space narrowing (grade .0, right panels).
These unadjusted data are a companion to the adjusted data
shown in Figure 2.
Found at: doi:10.1371/journal.pone.0009739.s006 (3.00 MB TIF)
Figure S4 Examples of biomarker concentrations and radio-
graphic features of OA in specific joint systems (adjusted). Point
estimates, 95% confidence intervals, and mixed-model regression
lines for mean serum log sHA (top), log sCOMP (middle), and log
uCTX2 (bottom) by number of joint faces affected by any
osteophyte (grade .0, left panels), and number of joint faces
affected by any joint space narrowing (grade .0, right panels).
Each panel represents an analysis that starts with the optimal
mixed-effects model for each biomarker as developed in the text,
and supplements it with the predictor of interest if it is not already
in the optimal model. The line in each plot represents the
prediction under the supplemented mixed-effects model. R2 values
are indicated giving the among-radiography class explained
variation. Corresponding p-values are (left to right by row):
1.961024, 0.039, 0.11, 3.361024, 1.361023, 0.18.
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Figure S5 Linear coefficients of biomarker associations with
radiographic features of OA (unadjusted). In this example, features
are fit independently, so that correlations among features are not
accounted for; the relationships between features and biomarkers
in this analysis are complicated by these correlations (compare
with Figure 3). Linear coefficients for each joint group and
radiographic feature are shown.
Found at: doi:10.1371/journal.pone.0009739.s008 (1.71 MB TIF)
Figure S6 Example of complex interaction of OST and JSN on
a biomarker concentration. Mean log uCTX2 concentrations
varied positively with JSN but negatively with OST. For the
depicted component of the mixed-effects model, R2=0.977,
p=5.461024.
Found at: doi:10.1371/journal.pone.0009739.s009 (1.05 MB TIF)
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